Epigenetic mutation load is weakly correlated with epigenetic age acceleration
Qi Yan1, Kimberly C Paul1, Ake T Lu2
1Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA 90095, USA.
Aging
|September 29, 2020
Summary
The accumulation of stochastic epigenetic mutations (SEMs) is linked to faster epigenetic aging. This study defines epigenetic mutation load (EML) and finds it correlates with multiple DNA methylation age acceleration measures.
Area of Science:
- Epigenetics
- Genomics
- Aging Research
Background:
- DNA methylation (DNAm) age is a key biomarker for aging.
- The relationship between DNAm age and stochastic epigenetic mutations (SEMs) is unclear.
- SEMs may indicate epigenetic maintenance system dysfunction.
Purpose of the Study:
- To define and assess epigenetic mutation load (EML).
- To investigate the association between EML and DNAm age acceleration.
- To identify biological pathways and genomic regions associated with EML and age acceleration.
Main Methods:
- Defined EML as the total number of SEMs per individual.
- Analyzed associations between EML and four DNAm age acceleration estimators in 6,388 participants across four studies.
- Conducted pathway enrichment analyses and examined genomic-region specific EML.
Main Results:
- EML positively correlated with chronological age (meta r = 0.171).
- EML associated with four epigenetic age acceleration measures (r ranging from 0.109 to 0.179).
- SEMs implicated signaling, neurogenesis, neurotransmitter, glucocorticoid, and circadian rhythm pathways; EML in repressed transcriptional regions correlated with faster age acceleration.
Conclusions:
- The accumulation of SEMs, measured by EML, is associated with accelerated epigenetic aging.
- Specific biological pathways and genomic regions may contribute to epigenetic mutation accumulation and aging.
- Findings suggest a role for epigenetic mutations in the aging process.
Related Concept Videos
Epigenetic Regulation
3.5K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.5K
Epigenetic Regulation
33.0K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.0K
Mismatch Repair
6.0K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.0K
Mismatch Repair
43.1K
Overview
43.1K
Spontaneous and Induced Mutations
1.4K
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
1.4K
Mutagenicity and Carcinogenicity
1.7K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.7K


